ALNA - Allena Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.3200
+0.0600 (+2.65%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.2600
Open2.2600
Bid1.8000 x 1200
Ask2.3400 x 1400
Day's Range2.1400 - 2.3400
52 Week Range1.5500 - 9.6000
Volume321,514
Avg. Volume409,806
Market Cap54M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-2.1210
Earnings DateNov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.14
  • Benzinga

    The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...

  • GlobeNewswire

    Allena Pharmaceuticals Provides Updates on Reloxaliase Development Program and Corporate Activities

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced updates on its clinical development programs for reloxaliase, a potential first-in-class, non-absorbed, orally administered enzyme for the treatment of severe hyperoxaluria, and several initiatives to realign resources to support the continued development of reloxaliase for patients with enteric hyperoxaluria (EH). Following positive topline results from URIROX-1 and further analysis of the data from the trial, Allena plans to re-engage with the FDA, with the request to discuss measures to potentially streamline its ongoing URIROX program through modifications to the adaptive URIROX-2 trial design.

  • GlobeNewswire

    Allena Pharmaceuticals to Present at Evercore ISI 2nd Annual HEALTHCONx Conference

    NEWTON, Mass., Nov. 25, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • Do Directors Own Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Shares?
    Simply Wall St.

    Do Directors Own Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Shares?

    A look at the shareholders of Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) can tell us which group is most powerful...

  • GlobeNewswire

    Allena Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the third quarter ended September 30, 2019 and also provided a business update. “We are excited about the presentation of positive topline results from URIROX-1 and Study 206 in EH patients that we presented at the American Society of Nephrology (ASN) Annual Meeting,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals.

  • Benzinga

    The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...

  • GlobeNewswire

    Allena Pharmaceuticals Reports Positive Reloxaliase Topline Results from URIROX-1 Trial and from Study 206

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced positive topline results from URIROX-1, its first Phase 3 pivotal trial evaluating reloxaliase in patients with enteric hyperoxaluria (EH), as well as additional data from Study 206, its Phase 2 trial evaluating reloxaliase in high-risk patients with EH and advanced chronic kidney disease (CKD). In both studies, treatment with reloxaliase led to substantial reductions in measures of oxalate burden.

  • 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts
    Kiplinger

    5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts

    When searching for big rewards, look no further than biotech stocks.Just be prepared for big risk, too.Biotechs offer gobs of price potential. That's because unlike many companies that can slowly but steadily build up their businesses over time, the survival of biotechnology companies (especially early on) hinges on just a few trials of their developing treatments. Eventual approval of the drug means life-sustaining revenues for the company, so positive trial news can send shares skyrocketing. Setbacks, however, can spark an exodus.While it's impossible for regular investors to gauge what's going on in testing labs, you can give yourself a small leg up by paying attention to the analysts who cover the biotechnology industry. If you find a stock that's mostly surrounded by bulls, that might be a signal that something rewarding is around the bend.Here are five biotech stocks that have a "Strong Buy" consensus analyst rating and have potential catalysts right around the corner. We've used TipRanks' Smart Score system to identify this health-care short list. Also remember that biotechnology stocks come with a considerable amount of risk, and that sharp drops are not uncommon. Consider using only a small allocation from the portion of your portfolio dedicated to aggressive investments. SEE ALSO: 10 High-Quality, High-Growth Stocks to Buy

  • GlobeNewswire

    Allena Pharmaceuticals to Present New Data on Reloxaliase and ALLN-346 Development Programs at Upcoming ASN Kidney Week and ACR/ARP Annual Meeting

    NEWTON, Mass., Oct. 17, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why
    Zacks

    Allena Pharmaceuticals, Inc. (ALNA) Upgraded to Buy: Here's Why

    Allena Pharmaceuticals, Inc. (ALNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • GlobeNewswire

    Allena Pharmaceuticals Completes Enrollment in Pivotal Phase 3 URIROX-1 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has completed enrollment in its pivotal Phase 3 URIROX-1 clinical trial. URIROX-1 is a multi-center, global, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of reloxaliase for the treatment of patients with enteric hyperoxaluria.

  • GlobeNewswire

    Allena Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Enteric Hyperoxaluria and Potential for Reloxaliase

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it will host a key opinion leader symposium on the unmet need in enteric hyperoxaluria and the potential for reloxaliase as a first-in-class therapy for patients. Scheduled to speak at the event is Gregory Tasian, M.D., Assistant Professor of Urology in Surgery and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania and Attending Pediatric Urologist at the Children’s Hospital of Philadelphia (CHOP). Additionally, Allena management will provide an overview of the market opportunity in enteric hyperoxaluria and its ongoing clinical development programs for reloxaliase, with a focus on URIROX-1, its first pivotal Phase 3 trial.

  • GlobeNewswire

    Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

    NEWTON, Mass., Aug. 29, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • GlobeNewswire

    Allena Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update

    Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today reported financial results for the second quarter ended June 30, 2019 and also provided a business update. “At Allena, we are committed to providing a first-in-class treatment for the full spectrum of patients with enteric hyperoxaluria (EH),” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “The initial data from Study 206 represent meaningful progress toward achieving this vision, as we showed for the first time reloxaliase’s ability to reduce both urine and plasma oxalate in patients with EH and impaired kidney function, including patients with advanced chronic kidney disease, dialysis-dependence, and transplantation.

  • GlobeNewswire

    Allena Pharmaceuticals to Present at 2019 Wedbush PacGrow Healthcare Conference

    NEWTON, Mass., Aug. 06, 2019 -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class,.

  • Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?
    Zacks

    Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?

    Within the Health Care Benefits segment, CVS Health (CVS) expects the government programs to go from strength to strength on the back of Medicare growth and major Medicaid wins.

  • Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?
    Zacks

    Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?

    Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.

  • Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
    Zacks

    Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

    Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.

  • What's in the Cards for DaVita (DVA) This Earnings Season?
    Zacks

    What's in the Cards for DaVita (DVA) This Earnings Season?

    DaVita (DVA) projects operating income within $460-$465 million for the second quarter.

  • What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
    Zacks

    What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?

    Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.

  • AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?
    Zacks

    AmerisourceBergen (ABC) Q3 Earnings: What's in the Offing?

    Better-than-expected performance at Pharmaceutical Distribution and higher revenues are likely to aid AmerisourceBergen (ABC) in Q3 earnings.

  • Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?
    Zacks

    Will Flagship Impella Drive ABIOMED's (ABMD) Q1 Earnings?

    ABIOMED's (ABMD) flagship Impella receives a slew of regulatory approvals.

  • Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
    Zacks

    Masimo (MASI) to Report Q2 Earnings: What's in the Offing?

    Masimo's (MASI) recent developments likely to show on second-quarter results.

  • What's in the Offing for DexCom's (DXCM) Earnings in Q2?
    Zacks

    What's in the Offing for DexCom's (DXCM) Earnings in Q2?

    Top-line growth and rising global awareness of the company's real-time CGM are likely to aid DexCom's (DXCM) Q2 earnings.

  • GlobeNewswire

    Allena Pharmaceuticals Announces $10.0 Million Registered Direct Offering of Common Stock

    Allena intends to use the net proceeds to fund its clinical development programs and for working capital and other general corporate purposes, including the advancement of its lead candidate reloxaliase, an orally-administered, recombinant oxalate-degrading enzyme that is being developed for the treatment of enteric hyperoxaluria. The securities described above are being offered pursuant to Allena’s shelf registration statement on Form S-3 (File No. 333-228656) filed with the Securities and Exchange Commission (SEC), which was declared effective on December 26, 2018.  A prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.  Copies of such prospectus supplement and accompanying base prospectus may also be obtained directly from Allena by contacting Allena Pharmaceuticals, Inc., Attn: Investor Relations, One Newton Executive Park, Suite 202, Newton, Massachusetts, 02462, or by telephone at 617-467-4577.